ArticleCureus2025
Atezolizumab-Induced Generalized Cutaneous Lichen Planus in a Patient With Metastatic Small Cell Lung Cancer Successfully Treated With Isotretinoin: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors, now widely used in treating various malignancies, increase the risk of autoimmune reactions and immune-related adverse events (irAEs), with skin toxicities being the most frequent. These agents enhance the immune response against tumors by blocking the suppression of cytotoxic T lymphocytes. Here, we report a rare case of generalized cutaneous lichen planus induced by atezolizumab, an immune checkpoint inhibitor administered for small cell lung cancer. After consulting with the oncologist, we opted to initiate isotretinoin as the first-line treatment. Considering the patient's oncologic status and multiple comorbidities, we aimed to avoid systemic corticosteroids due to their potential side effects. This case was effectively managed with low-dose oral isotretinoin alongside high-potency topical corticosteroids. It emphasizes the need to consider retinoids as a potential treatment option for various dermatological conditions beyond acne. Isotretinoin may be beneficial in treating lichen planus by influencing cellular proliferation and promoting epithelial differentiation, though its exact mechanism remains uncertain. Additionally, it has notable anti-inflammatory effects and modulates immune responses. In such cases, isotretinoin may also enhance the therapeutic effects of topical corticosteroids through a synergistic interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.